Psychedelics and Psychedelic-Assisted Psychotherapy
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms “clinical trial,” “therapy,” or “imaging” in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “breakthrough therapies” for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, comorbid conditions such as suicidality and substance use disorders further complicate research efforts (13, 18, 20, 21).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [21]
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Reiff et al., 2020
In the citing paper
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124-126].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [126]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Ketamine NMDA antagonist Deficits in vigilance, verbal fluency, delayed recall, and tests of frontal lobe function (121) Derealization, depersonalization (8, 120, 121, 124); illusions in all sensory domains and perceptual alterations (121) Amotivation, emotional dulling, hostility (121); anxiety (121, 123) Improved mo…”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Journal of Transpersonal Psychology
(1977) · Journal of Humanistic Psychology · doi:10.1177/002216787701700308 · Cited by 1,732
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4×
“The mean change in HAM-D score 21 days after drug administration was 211.4. a AASE=Alcohol Abstinence Self-Efficacy Scale; BDI=Beck Depression Inventory; CAPS=Clinician-Administered PTSD Scale; LSD=lysergic acid diethylamide; DMT=N,N-dimethyltryptamine; HADS=Hospital Anxiety and Depression Scale; HAM-A=Hamilton Anxiet…”
BackgroundMethodInfluentialDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“(23) conducted an openlabel pilot study evaluating the feasibility and efficacy of”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Research works printed but not linked: 13
- Lee M, 1992, Acid Dreams: The Complete History of LSD: The CIA, The Sixties, and Beyond
- Darling DC, 2006, Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Abramson HA: The Use of LSD in Psychotherapy, in Transactions of a Conference on d-Lysergic Acid Diethylamine (LSD-25). New York: Josiah Macy Jr. Foundation Publications, 1959
- Grof S, 1977, The Human Encounter With Death
- Labate BC, 2009, Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays
- Holland J, 2001, Ecstasy: The Complete Guide
- Mithoefer MC, 2013, A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder
- Grof S, 2008, LSD Psychotherapy
- Kalant H, 2001, CMAJ, 165, 917
- Preller KH, 2018, Behavioral Neurobiology of Psychedelic Drugs, 221
- Aarde SM, 2017, Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 145
- Heifets BD, JAMA Psychiatry
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationThe Critical Relationship Between Anxiety and Depression
Kalin, N. H. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20030305 · Cited by 702
“Also included in this issue is a review of the data addressing the reemergence of the use of psychedelic drugs in psychiatry, particularly for the treatment of depression, anxiety, and PTSD (23).”
BackgroundSelf-citationGukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073759 · Cited by 425
“, 2018), there remains concern for its potential to cause harm or encourage substance misuse in vulnerable populations (Reiff et al., 2020; Schatzberg, 2020).”
BackgroundTowards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“Classic psychedelics have been shown to catalyze relatively long-lasting improvements in mental health after a small number of doses, especially when combined with psychotherapy [2].”
BackgroundStructure-based discovery of nonhallucinogenic psychedelic analogs
Cao, D., Yu, J., Wang, H., Luo, Z., Liu, X., He, L., Qi, J., Fan, L., Tang, L., Chen, Z., et al. (2022) · Science · doi:10.1126/science.abl8615 · Cited by 312
The role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
The promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221116926 · Cited by 178
“Despite relevant pharmacological distinctions, both MDMA and serotonergic hallucinogens are often classified as “psychedelics” and administered under similar therapeutic conditions (Garcia-Romeu et al., 2016; Reiff et al., 2020).”
BackgroundGoodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.108 · Cited by 173
Preparing for the bursting of the psychedelic hype bubble.
Yaden, D. B., Potash, J. B., & Griffiths, R. R. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2546 · Cited by 162
Nemeroff, C. B. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060845 · Cited by 172
Self-citationYao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 173
“Psychedelics can reduce morbidity in patients with various forms of depression and neuroses, anxiety disorders, personality disorders, sexual dysfunctions, and alcohol dependence (Reiff et al., 2020).”
Celidwen, Y., Redvers, N., Githaiga, C., Calambás, J., Bedriñana, K. G. A., Chindoy, M. E., Vitale, R., Rojas, J. N., Mondragón, D., Rosalío, Y. V., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100410 · Cited by 195
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Accelerated TMS - moving quickly into the future of depression treatment
van Rooij, S. J. H., Arulpragasam, A. R., McDonald, W. M., & Philip, N. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01599-z · Cited by 164
“While psilocybin assisted psychotherapy holds promise for continued investigation, the use of psilocybin in depression more broadly has only begun to be examined [18].”
BackgroundSelf-citationPsilocybin-assisted therapy for depression: A systematic review and meta-analysis
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115531 · Cited by 134
Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., & Goldberg, S. B. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.073 · Cited by 157
Depression: Biological markers and treatment
Erjavec, G. N., Šagud, M., Perković, M. N., Štrac, D. Š., Konjevod, M., Tudor, L., Uzun, S., & Pivac, N. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110139 · Cited by 136
Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E. S., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., et al. (2024) · Med · doi:10.1016/j.medj.2024.01.005 · Cited by 141
Novel drug developmental strategies for treatment‐resistant depression
Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B., & Helyes, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15753 · Cited by 132
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Psychedelic medicine: safety and ethical concerns
Anderson, B. T., Danforth, A. L., & Grob, C. S. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30146-2 · Cited by 107
Registered clinical studies investigating psychedelic drugs for psychiatric disorders
Siegel, A. N., Meshkat, S., Benitah, K., Lipsitz, O., Gill, H., Lui, L. M. W., Teopiz, K. M., McIntyre, R. S., & Rosenblat, J. D. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.019 · Cited by 97
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Hadar, A. A., David, J., Shalit, N., Roseman, L., Gross, R., Sessa, B., & Lev‐Ran, S. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2022254 · Cited by 115
“The initial search terms were selected based on the most recent comprehensive reviews focusing on the use of psychedelic compounds for human research and therapy (Reiff et al. 2020).”
BackgroundBrennan, W., & Belser, A. B. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866018 · Cited by 90
Risks and Benefits of Cannabis and Cannabinoids in Psychiatry
Hill, K. P., Gold, M. S., Nemeroff, C. B., McDonald, W. M., Grzenda, A. L., Widge, A. S., Rodríguez, C. I., Kraguljac, N. V., Krystal, J. H., & Carpenter, L. L. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21030320 · Cited by 98
Self-citationPsychedelics, Sociality, and Human Evolution
Rodríguez Arce, J. M., & Winkelman, M. J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.729425 · Cited by 86
“In contemporary clinical contexts, psychedelics have effective psychiatric applications, particularly in the treatment of stress-related disorders (dos Santos et al., 2016; Garcia-Romeu et al., 2016; Carhart-Harris and Goodwin, 2017; Johnson and Griffiths, 2017; Goldberg et al., 2020a; Luoma et al., 2020; Reiff et al.…”
BackgroundAcute psilocybin enhances cognitive flexibility in rats
Pacheco, A. T., Olson, R. J., Garza, G., & Moghaddam, B. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01545-z · Cited by 106
Mason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.004 · Cited by 102
Why was early therapeutic research on psychedelic drugs abandoned?
Hall, W. (2021) · Psychological Medicine · doi:10.1017/s0033291721004207 · Cited by 104
“…these drugs are used if they are approved to treat depression and PTSD, in light of the encouraging results of phase 2 trials on psilocybin for depression and MDMA for PTSD (Jerome et al., 2020; Luoma, Chwyl, Bathje, Davis, & Lancelotta, 2020; Muttoni, Ardissino, & John, 2019; Reiff et al., 2020).”
BackgroundThe Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 102
Thrul, J., & Garcia‐Romeu, A. (2021) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2021.1897331 · Cited by 92
“As such, both psilocybin and MDMA have been granted ‘breakthrough therapy’ designation by the US Food and Drug Administration (FDA), and pending positive outcomes of ongoing and upcoming clinical trials, could emerge as a novel treatment paradigm with considerable ramifications for mental healthcare (Reiff et al., 202…”
BackgroundInfluentialThe therapeutic potential of psilocybin: a systematic review
van Amsterdam, J., & van den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047929 · Cited by 74
“In most studies, no detailed description of the psychotherapeutic part of the psilocybin treatment is provided although it is generally assumed that psychotherapeutic support in preparatory sessions before and psychotherapeutic support during the psychedelic sessions facilitate positive and transformative experiences…”
Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300501 · Cited by 82
Research abuses against people of colour and other vulnerable groups in early psychedelic research
Strauss, D., de la Salle, S., Sloshower, J., & Williams, M. T. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2021-107262 · Cited by 77
Sarris, J., Perkins, D., Cribb, L., Schubert, V., Opaleye, E., Bouso, J. C., Scheidegger, M., Aicher, H., Simonova, H., Horák, M., et al. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100098 · Cited by 73
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
“5,6 Psychedelics are currently receiving increasing interest from researchers and investors, although several barriers to translating research into clinical practice have been recognized and include the need for clinical supervision of hallucinogenic experiences.”
Sumner, R. L., Chacko, E., McMillan, R. L., Spriggs, M. J., Anderson, C., Chen, J., French, A., Jung, S., Rajan, A., Malpas, G. A., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121998321 · Cited by 78
“…downstream glutamatergic action and the consequences for neural plasticity provide plausible shared mechanisms by which ketamine, LSD, psilocybin, ayahuasca, MDMA, and other psychedelic drugs may exert their therapeutic effects (Ly et al., 2018; Reiff et al., 2020; Vollenweider and Kometer, 2010).”
BackgroundInfluentialCritical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.710004 · Cited by 84
Li, N.-X., Hu, Y.-R., Chen, W.-N., & Zhang, B. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.041 · Cited by 72
The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision
Smith, D. T., Faber, S. C., Buchanan, N. T., Foster, D., & Green, L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.774736 · Cited by 81
“The destigmatization of psychedelics as a category remains an ongoing process, but the destigmatization of Blacks using psychotherapeutics remains further out of reach (74).”
BackgroundTherapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
“Most clinical trials with MDMA and psilocybin have a similar structure involving three phases: preparation, drug administration, and integration therapy [186, 187].”
BackgroundClassics in Chemical Neuroscience: Amitriptyline
McClure, E. W., & Daniels, R. N. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00467 · Cited by 78
The Rapid Rise in Investment in Psychedelics—Cart Before the Horse
Phelps, J., Shah, R. N., & Lieberman, J. A. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.3972 · Cited by 70
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Giluk (2009) · doi:10.1017/s003329172000389x · Cited by 68
“…may include the use of psilocybin for the treatment of anxiety and depression (Goldberg et al., 2020), although 2Since the time of submission, Romeo et al. (2020) published a meta-analysis of eight studies focused on the effects of classical psychedelics on depression symptoms. ayahuasca and…”
BackgroundJohnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 73
Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions
Fagan, H. A., & Baldwin, D. S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2211767 · Cited by 94
“There is some evidence for the use of psilocybin in the treatment of depression [92], and limited evidence to support a potential anxiolytic effect of these agents.”
Stauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00169 · Cited by 65
Barnett, B. S., Beaussant, Y., King, F., & Doblin, R. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1957183 · Cited by 70
“Following decades of slow progress secondary to stigma, regulatory barriers, and limited research funding, medicinal psychedelic research has begun accelerating in recent years (Reiff et al. 2020).”
BackgroundInfluentialAncient Roots of Today’s Emerging Renaissance in Psychedelic Medicine
George, D. R., Hanson, R., Wilkinson, D., & Garcia‐Romeu, A. (2021) · Culture Medicine and Psychiatry · doi:10.1007/s11013-021-09749-y · Cited by 92
“While the shaman of the Andes might look askance at the biomedical laboratories where scientists now study altered states, these clinics have become a major proving ground for the re-legitimation of psychedelics in Western culture (Garcia-Romeu et al. 2016; Reiff et al. 2020).”
BackgroundNovel ethical and policy issues in psychiatric uses of psychedelic substances
Smith, W., & Appelbaum, P. S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109165 · Cited by 72
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry
Barber, G., & Dike, C. C. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220525 · Cited by 77
Chen, G., Chen, L., Zhang, Y., Li, X., Lane, R., Lim, P., Daly, E. J., Furey, M. L., Fedgchin, M., Popova, V., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab084 · Cited by 70
“However, the extant evidence suggests both the antidepressant and dissociative effects of ESK are mediated via NMDAR antagonism (Saad et al., 2020), as supported by direct (Stone et al.”
The varieties of psychedelic law
Marks, M. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109399 · Cited by 73
Page, C. E., Epperson, C. N., Novick, A. M., Duffy, K. A., & Thompson, S. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02625-2 · Cited by 80
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124 – 126].”
Rosenblat, J. D., Husain, M. I., Lee, Y. L., McIntyre, R. S., Mansur, R. B., Castle, D. J., Offman, H., Parikh, S. V., Frey, B. N., Schaffer, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221111371 · Cited by 70
“, acute cognitive, perceptual, psychological and emotional effects).(9,12) While the debate continues regarding the inclusion of other mind-altering substances (e.”
BackgroundInfluentialMDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
Self-citationBarber, G., Nemeroff, C. B., & Siegel, S. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.22010073 · Cited by 63
Self-citationMaia, L. O., Beaussant, Y., & Garcia, A. C. M. (2022) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2022.01.024 · Cited by 72
Singewald, N., Sartori, S. B., Reif, A., & Holmes, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109418 · Cited by 67
“psychotherapy, based on the notion that they enhance acceptance of and compliance with psychotherapy to thereby enhance the long-term therapeutic efficacy (Reiff et al., 2020).”
BackgroundSANTOS, R. G. D., Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. C. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s300656 · Cited by 76
“Both MDMA and psilocybin have been designated by the FDA as “breakthrough therapies” and in the case of MDMA both the FDA and the Israeli Agency of Medicines have authorized its use as a compassionate medicine.(32) MDMA has different mechanisms of action from those of classic hallucinogens.”
BackgroundTwo Models of Legalization of Psychedelic Substances: Reasons for Concern
Smith, W., & Appelbaum, P. S. (2021) · JAMA · doi:10.1001/jama.2021.12481 · Cited by 63
The challenges ahead for psychedelic ‘medicine’
Muthukumaraswamy, S. D., Forsyth, A., & Sumner, R. L. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221081763 · Cited by 62
“So, while psychedelics have shown early promise in the treatment of mental health disorders (see Reiff et al., 2020), with all the excitement around the potential of psychedelic medicine, it is important to remain objective and realistic about the difficult path that lies ahead given the pandemic…”
BackgroundThe Emerging Field of Psychedelic Psychotherapy
Barber, G., & Aaronson, S. T. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01363-y · Cited by 68
Hull, T. D., Malgaroli, M., Gazzaley, A., Akiki, T. J., Madan, A., Vando, L., Arden, K., Swain, J., Klotz, M., & Paleos, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.004 · Cited by 58
“…study (McInnes et al., 2022) for KIT, however, response and remission rates for this sample are similar to, if slightly stronger than, those previously reported (aan het Rot et al., 2010; Fava et al., 2020; Lara et al., 2013; Lener et al., 2017; McInnes et al., 2022; Phillips et al., 2019).”
Mendes, F. R., Costa, C. D. S., Wiltenburg, V. D., Morales-Lima, G., Fernandes, J. A. B., & Filev, R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100025 · Cited by 72
Pattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 78
“There is growing evidence that psychedelics can have a positive impact on mental health, particularly when applied as psychedelic-assisted therapy (Reiff et al. 2020).”
Oña, G., & Bouso, J. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.035 · Cited by 65
Kloft, L., Monds, L. A., Blokland, A., Ramaekers, J. G., & Otgaar, H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.012 · Cited by 58
Maples‐Keller, J. L., Norrholm, S. D., Burton, M. S., Reiff, C. M., Coghlan, C., Jovanović, T., Yasinski, C. W., Jarboe, K. S., Rakofsky, J. J., Rauch, S. A. M., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069124 · Cited by 62
“Recently MDMA research has significantly increased with growing evidence for the safety and efficacy of MDMA-assisted therapy (Feduccia et al., 2019; Jerome et al., 2020; Mitchell et al., 2021; Mithoefer et al., 2018; Oehen et al., 2013; Reiff et al., 2020; Warren et al., 2014).”
BackgroundSelf-citationAntidepressant Effects of Psilocybin in the Absence of Psychedelic Effects
Rosenblat, J. D., Leon-Carlyle, M., Ali, S., Husain, M. I., & McIntyre, R. S. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220835 · Cited by 62
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
Perkins, D., Sarris, J. J., Rossell, S. L., Bonomo, Y. A., Forbes, D., Davey, C. G., Hoyer, D., Loo, C. K. A., Murray, G., Hood, S. D., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867421998785 · Cited by 65
Perkins, D., Opaleye, E. S., Šimonová, H., Bouso, J. C., Tófoli, L. F., Coelho, N. L. G., Schubert, V., & Sarris, J. J. (2021) · Drug and Alcohol Review · doi:10.1111/dar.13348 · Cited by 69
“Here the PEQ-S was associated with substantial increases in the odds of lower alcohol consumption and no recent use of any drug use for those with a prior AUD or DUD respectively [1].”
Chen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106837 · Cited by 63
Belouin, S. J., Averill, L. A., Henningfield, J. E., Xenakis, S. N., Donato, I., Grob, C. S., Berger, A., Magar, V., Danforth, A. L., & Anderson, B. T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109214 · Cited by 54
Wießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Feilding, A., Ribeiro, S. T. G., & Tófoli, L. F. (2021) · Psychological Medicine · doi:10.1017/s0033291721002531 · Cited by 58
“On the other hand, it was applied as a therapeutic tool for conditions including alcoholism and mood disorders (Krebs & Johansen, 2012; Reiff et al., 2020).”
MethodWolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 52
“Until now, most clinical applications of psychedelic agents have been in the context of psychotherapy [9].”
BackgroundPharmacotherapeutic Strategies and New Targets in OCD
Pittenger, C. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_204 · Cited by 58
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Mitchell, J., & Anderson, B. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01656-7 · Cited by 56
Ethnoracial inclusion in clinical trials of psychedelics: a systematic review
Hughes, M. E., & Garcia‐Romeu, A. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102711 · Cited by 52
Active mechanisms of ketamine-assisted psychotherapy: A systematic review
Joneborg, I., Lee, Y. L., Vincenzo, J. D. D., Ceban, F., Meshkat, S., Lui, L. M. W., Fancy, F., Rosenblat, J. D., & McIntyre, R. S. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.030 · Cited by 58
Pędzich, B. D., Rubens, S., Sekssaoui, M., Pierre, A., Schuerbeek, A. V., Marin, P., Bockaert, J., Valjent, E., Bécamel, C., & Bundel, D. D. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01324-2 · Cited by 56
Breeksema, J. J., Niemeijer, A. R., Kuin, B., Veraart, J. K. E., Kamphuis, J., Schimmel, N., van den Brink, W., Vermetten, E. H. G. J. M., & Schoevers, R. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.948115 · Cited by 52
“The phenomenology of these effects overlaps with the psychedelic effects of classic serotonergic psychedelics (13, 14), including visual and auditory perceptual changes, altered proprioception, alterations in conscious states, experiencing detachment from the world or self, and mystical experiences (15–17).”
BackgroundOrt, A., Smallridge, J. W., Sarasso, S., Casarotto, S., von Rotz, R., Casanova, A., Seifritz, E., Preller, K. H., Tononi, G., & Vollenweider, F. X. (2023) · iScience · doi:10.1016/j.isci.2023.106589 · Cited by 59
Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes
Matzopoulos, R., Morlock, R., Morlock, A., Lerer, B., & Lerer, L. B. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780696 · Cited by 59
“…to restrictive legislative policies, the past decade has seen an exceptional resurgence of research into the therapeutic potential of psychedelics, particularly psilocybin (2), for the treatment of conditions including depression, post-traumatic stress disorder (PTSD) and addiction (3)(4)(5).”
The role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 51
“These medications work on a timescale of hours to days rather than weeks to months [13 – 16].”
BackgroundBrewerton, T. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1149433 · Cited by 46
Wells, A., Fernandes, M. T. C. F., & Reynolds, L. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00294 · Cited by 56
“Similarly, Reiff et al. (2020) reported on the ef fi cacy of MDMA and psilocybin in treating symptoms of PTSD and depression, but noted that confounders, patient bias, and challenges associated with blinding remain.”
Mindfulness meditation and psychedelics: potential synergies and commonalities
Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43
“This approach aims to enhance emotional processing, encourage introspection, and facilitate breakthroughs in therapy [34].”
BackgroundYu, Z., Burback, L., Winkler, O., Xu, L., Dennett, L., Vermetten, E. H. G. J. M., Greenshaw, A. J., Li, X., Milne, M., Wang, F., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1386321 · Cited by 50
Schipper, S., Nigam, K. B., Schmid, Y., Piechotta, V., Ljuslin, M., Beaussant, Y., Schwarzer, G., & Boehlke, C. S. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015383.pub2 · Cited by 65
Altered states phenomena induced by visual flicker light stimulation
Bartossek, M. T., Kemmerer, J., & Schmidt, T. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253779 · Cited by 46
Motives for the use of serotonergic psychedelics: A systematic review
Basedow, L. A., & Kuitunen‐Paul, S. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13480 · Cited by 46
Lafrance, A., Strahan, E., Bird, B. M., St. Pierre, M., & Walsh, Z. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211048049 · Cited by 40
“The increase in research over the past decade has once again shown promising results in finding, for example, that psychedelics can significantly reduce symptoms of depression, anxiety, and substance use (see Reiff et al., 2020, for review).”
BackgroundVilliger, D., & Trachsel, M. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2022-108816 · Cited by 45
The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy
Page, L., Rehman, A., Syed, H., Forcer, K., & Campbell, G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.743599 · Cited by 44
Brewerton, T. D., Gavidia, I., Suro, G., & Perlman, M. M. (2023) · Journal of Eating Disorders · doi:10.1186/s40337-023-00773-4 · Cited by 38
Catalysts for change: the cellular neurobiology of psychedelics
Banks, M. I., Zahid, Z., Jones, N., Sultan, Z. W., & Wenthur, C. J. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-05-0340 · Cited by 47
“Over the past two decades, as human subject research on psychedelics has begun to revive, several small clinical trials have shown the remarkable potential of psychedelics to treat psychiatric disorders (Goldberg et al., 2020; Reiff et al., 2020).”
Background
Metadata
- Authors
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R.
- Affiliations
- Emory University (US)
- Department of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2020-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 391-410
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3006905788
- Cited by
- 649
- References
- 120
- Citations by year
- 2026: 93 · 2025: 126 · 2024: 129 · 2023: 113 · 2022: 102 · 2021: 60 · 2020: 26
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG059307)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, ayahuasca, MDMA, post-traumatic stress disorder, treatment-resistant depression, cancer-related anxiety, substance use disorders, trauma and stress-related disorders, end-of-life care
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin, Psychotherapy, N-Methyl-3,4-methylenedioxyamphetamine, Evidence-Based Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.